JIANGSU TINGSN TECHNOLOGY CO., LTD._Topimd.com-International Medical Devices

Main Business：Intracardiac echocardiography
Company Type：Company
Operating Model：Manufacturers
Establishment：2017

Tingsn Technology was co-founded by senior scientists in the ultrasound industry, senior cardiologists and serial entrepreneurs, with its headquarters located in Nanjing, China. To date, the company has been granted 25 domestic patents including 9 invention patents and 2 overseas patents, with an additional 19 patent applications in progress. Rated as a potential unicorn enterprise in 2023, Tingsn has established R&D centers in China and the United States. Led by overseas returnee doctors, it has built an international R&D team, and maintains in-depth cooperation with globally renowned clinical groups and top domestic acoustic research institutions.

The company focuses on technological innovation of ultrasound applications in cardiac electrophysiology and structural heart disease. Through the integrated application of imaging, mapping and ablation energy, it commits to delivering more effective treatment solutions for patients with heart diseases. Its core product pipeline includes 2D intracardiac ultrasound imaging systems, 4D intracardiac ultrasound imaging systems, ultrasound three-dimensional mapping systems, and ultrasound energy therapy systems.

Headquartered in the Sino-Danish Life Science Industrial Park, Jiangbei New Area, Nanjing, the company operates a nearly 4,800-square-meter R&D and manufacturing center equipped with high-precision testing instruments and automated production lines. To better explore overseas markets and facilitate global technical exchanges and innovation, Tingsn has also set up an overseas R&D center in Massachusetts, USA.

Up to now, the company has completed three rounds of financing with a total amount exceeding 200 million RMB. Its flagship product, the single-use intracardiac ultrasound diagnostic catheter, entered the NMPA Innovative Medical Device Special Review Channel in January 2023, and officially obtained the registration certificate (NMPA Registration No. 20233061761) in November of the same year. It is one of the first domestically developed high-end intracardiac ultrasound diagnostic catheters approved for commercial use in China.

Moving forward, Tingsn Technology will stay committed to breaking the foreign capital monopoly in the domestic market and maintaining technological leadership among domestic peers. Dedicated to making advanced cardiac treatments accessible to more patients, including those in underdeveloped regions, the company strives to become an influential Made-in-China medical device brand with global competitiveness.